VOGX Stock Chart & Stats
$20.39
$1.64(8.75%)
―
--
Day’s Range― - ―
52-Week Range$12.95 - $38.41
Previous CloseN/A
VolumeN/A
Average Volume (3M)130.76K
Market Cap
$278.53M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-14.29
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding14,855,087
10 Day Avg. Volume112,344
30 Day Avg. Volume130,759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$42.00Price Target Upside― Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Vogenx, Inc. News
VOGX FAQ
What was Vogenx, Inc.’s price range in the past 12 months?
Vogenx, Inc. lowest stock price was $12.95 and its highest was $38.41 in the past 12 months.
What is Vogenx, Inc.’s market cap?
Vogenx, Inc.’s market cap is $278.53M.
When is Vogenx, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Vogenx, Inc.’s earnings last quarter?
Currently, no data Available
Is Vogenx, Inc. overvalued?
According to Wall Street analysts Vogenx, Inc.’s price is currently Undervalued.
Does Vogenx, Inc. pay dividends?
Vogenx, Inc. does not currently pay dividends.
What is Vogenx, Inc.’s EPS estimate?
Vogenx, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vogenx, Inc. have?
Vogenx, Inc. has 14,855,087 shares outstanding.
What happened to Vogenx, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vogenx, Inc.?
Currently, no hedge funds are holding shares in VOGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vogenx, Inc. Stock Smart Score
Company Description
Vogenx, Inc.
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.